• 1
    Gerin JL. Experimental WHV infection of woodchucks: an animal model of hepadnavirus-induced liver cancer. Supp 1 Gastroenterol Jpn 1990; 25:3842.MEDLINE
  • 2
    Tennant B, Gerin J. The woodchuck model of hepatitis B infection. In: IArias J, BoyerN, FaustoW, JacobyD, SchachterD, Shafritz eds. The Liver: Biology and Pathobiology. New York: Raven, 1994;14551466.
  • 3
    Tencza MG, et al. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J Med Virol 1997; 51:616.MEDLINE
  • 4
    Korba BE, Xie H, Wright KN, Hornbuckle WE, Gerin JL. Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology 1996; 23:958963.MEDLINE
  • 5
    Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998; 28:179191.MEDLINE
  • 6
    Tennant B, Baldwin B, Hornbuckle W, Korba B, Cote P, Gerin J. Animal models in the preclinical assessment of therapy for viral hepatitis. Antiviral Ther 1997; 1:4752.
  • 7
    Tennant B, Korba B, Cote P, Baldwin B, Graham L, Hornbuckle W, Gerin J. The woodchuck model in antiviral drug development. In: MRizzetto R, PurcellJ, GerinG, Verme eds. Viral Hepatitis and Liver Disease. Torino, Italy: Edizioni Minerva Medica SPA, 1997;754757.
  • 8
    Tennant B, Peek S, Tochkov I, Baldwin B, Hornbuckle W, Korba B, Cote P, Gerin J. The woodchuck in preclinical assessement of therapy for hepatitis B infection. In: RSchinazi J, SommadossiH, Thomas eds. Therapies for Viral Hepatitis. New York: International Medical Press, 1998;171176.
  • 9
    Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Tennant B, et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998; 245:1832.MEDLINE
  • 10
    Hurwitz S, Tennant B, Korba B, Gerin J, Schinazi R. Viral pharmacodynamics of (−)-β-2′,3′-dideoxy-3′-thiacytidine in chronically infected woodchucks compared to humans. Antimicrob Agents Chemother 1998; 42:28042809.MEDLINE
  • 11
    Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998; 4:610614.MEDLINE
  • 12
    Gangemi J, Korba B, Tennant B, Udea H, Jay G. Antiviral and anti-proliferative activities of alpha-interferon in experimental hepatitis B virus infections. Antiviral Ther 1997; 1:6470.
  • 13
    Gangemi D, Korba B, Tennant B, Gerin J, Cote P, Ueda H, Jay G. Antiviral and anti-proliferative activities of α-interferon in experimental hepatitis B virus infections. In: RSchinazi J, Sommadossi eds. Therapies for Viral Hepatitis. Atlanta: International Medical Press, 1998;195203.
  • 14
    Gerin J, Korba B, Cote P, Tennant B. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. In: TBlock D, JungkindR, CrowellM, Denison eds. Innovations in Antiviral Development and the Detection of Virus Infection. New York: Plenum, 1992;121123.
  • 15
    Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, et al. In vivo antiviral activity and pharmacokinetics of (−)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus–infected woodchucks. Antimicrob Agents Chemother 1997; 41:20762082.MEDLINE
  • 16
    Fiume L, DiStefano G, Busi C, Mattioli A, Rapicetta M, Giuseppetti R, Ciccaglione AR, et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology 1995; 22:10721077.MEDLINE
  • 17
    Bartholomew RM, Carmichael EP, Findeis MA, Wu CH, Wu GY. Targeted delivery of antisense DNA in woodchuck hepatitis virus–infected woodchucks. J Viral Hepatol 1995; 2:273278.
  • 18
    Nordenfelt E, Widell A, Hansson BG, Lofgren B, Moller-Nielsen C, Oberg B. No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production. Acta Pathol Microbiol Immunol Scand [B] 1982; 90:449451.
  • 19
    Venkateswaran PS, Millman I, Blumberg BS. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1987; 84:274278.MEDLINE
  • 20
    Chu C, Hoong J, Yogensok C, Du J, Lee K, Chun B, Boudinot F, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antiviral Ther 1998; 3:113124.
  • 21
    Tennant BC, Hornbuckle WE, Baldwin BH, King JM, Cote P, Popper H, Purcell RH, et al. Influence of age on the response to experimental woodchuck hepatitis virus infection. In: AJZuckerman eds. Viral Hepatitis and Liver Disease. New York: A.R. Liss, Inc, 1988;462464.
  • 22
    Korba BE, Wells F, Tennant BC, Yoakum GH, Purcell RH, Gerin JL. Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. J Virol 1986; 58:18.MEDLINE
  • 23
    Morrey J, Sidwell R, Korba B, Guidotti L. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antiviral Ther 1998; 3:5970.
  • 24
    Cote PJ, Engle RE, Langer CA, Ponzetto A, Gerin JL. Antigenic analysis of woodchuck hepatitis virus surface antigen with site-specific radioimmunoassays. J Virol 1984; 49:701708.MEDLINE
  • 25
    Cote PJ, Roneker C, Cass K, Schodel F, Peterson D, Tennant B, DeNoronha F, et al. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol 1993; 6:161169.MEDLINE
  • 26
    Ponzetto A, Cote PJ, Ford EC, Purcell RH, Gerin JL. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus. J Virol 1984; 52:7076.MEDLINE
  • 27
    Wong DC, Shih JW, Purcell RH, Gerin JL, London WT. Natural and experimental infection of woodchucks with woodchuck hepatitis virus, as measured by new, specific assays for woodchuck surface antigen and antibody. J Clin Microbiol 1982; 15:484490.MEDLINE
  • 28
    Lok AS, Wilson LA, Thomas HC. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J Antimicrob Chemother 1984; 14:9399.MEDLINE
  • 29
    Thomas HC, Scully LJ, Lever AM, Yap I, Pignatelli M. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies of hepatitis B virus carrier treatment: identification of factors influencing response rates. Supp 1 Infection 1987; 15:S26S31.MEDLINE
  • 30
    Kao JH, Lai MY, Chen W, Chen PJ, Chen DS. Efficacy of ribavirin plus interferon alpha on viremia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone. J Gastroenterol Hepatol 1998; 13:1249.MEDLINE
  • 31
    Tappero G, Ballare M, Farina M, Negro F. Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. J Hepatol 1998; 29:10331034.MEDLINE
  • 32
    Lemon SM, Bancroft WH. Lack of specific effect of adenine arabinoside, human interferon, and ribavirin on in vitro production of hepatitis B surface antigen. J Infect Dis 1979; 140:798801.MEDLINE
  • 33
    Fried MW, Fong TL, Swain MG, Park Y, Beames MP, Banks SM, Hoofnagle JH, et al. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J Hepatol 1994; 21:145150.MEDLINE
  • 34
    Gallian P, De Lamballerie X, Lehucher MP, Dhiver C, Ravaux I. Absent inhibition of hepatitis B virus replication by azidothymidine in patients chronically coinfected by HIV-1 and HBV. New Microbiol 1996; 19:167169.MEDLINE
  • 35
    Janssen HL, Berk L, Heijtink RA, Ten Kate FJ, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. Hepatology 1993; 17:383388.MEDLINE
  • 36
    Gilson RJ, Hawkins AE, Kelly GK, Gill SK, Weller IV. No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection. Aids 1991; 5:217220.MEDLINE
  • 37
    Jaeckel E, Manns MP. Experience with lamivudine against hepatitis B virus. Intervirology 1997; 40:322336.MEDLINE
  • 38
    Dienstag J, Schiff E, Mitchell M, Gitlin N, Lissoos T, Condreay L, Garrett L. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24:188A.
  • 39
    Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241244.MEDLINE
  • 40
    Tyrrell D, Mitchell M, de Mann R, Schalm S, Main J, Thomas H, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18:112A.
  • 41
    Boyd M, Safrin S, Kern E. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance pattern. Antiviral Chem Chemother 1993; 4:311.
  • 42
    Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40:337342.MEDLINE
  • 43
    Kruger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Boker KH, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2:253262.MEDLINE
  • 44
    Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3:211215.MEDLINE
  • 45
    Ganem D. Hepadnaviridae: The viruses and their replication. In: BNFields P, Howley eds. Fields Virology. Philadelphia: Lippincott-Raven, 1997;27032737.
  • 46
    Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998; 42:21322137.MEDLINE
  • 47
    Ono N, Iwayama S, Suzuki K, Sekiyama T, Nakazawa H, Tsuji T, Okunishi M, et al. Mode of action of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl) cycloprop-1′-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob Agents Chemother 1998; 42:20952102.MEDLINE